Navigation Links
Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:12/15/2010

EAST BRUNSWICK, N.J., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 11:00 a.m. Pacific Time.  The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.  

A live webcast of the presentation and the question and answer session can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
(Date:5/23/2016)... 23, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced ... Internship programs. The hands-on learning experience is a 12-week ... paid Fellowship and Internship programs ... Fellows and interns are provided optional housing free of ... at the Riverfront Residence Hall to foster communication ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health insurance ... 10% over last year, according to data in the forthcoming AIS’s Directory of ... stable, with a slight decrease in risk-based groups and a slight increase in ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, on May ... transplant in the United States . The 64-year-old patient who received the transplant had ... could restore not only a natural appearance, but also urinary and sexual function for ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... In light ... residents aware of the potential of contaminated well water throughout the Houston area. , ... supplied with well water that’s exposed to contaminants. Residents may not even be aware ...
(Date:5/24/2016)... ... 24, 2016 , ... Aloria Health Announces Opening of Eating ... , Aloria Health, specializing in a re-imagined, client-oriented approach to the treatment of ... treatment facility for outpatient, day treatment and residential care. Aloria Milwaukee will open ...
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion Safety Systems , ... labels , has been featured in the National Electrical Manufacturers Association’s (NEMA) newsletter, ... electroindustry professionals with manufacturer, regulatory, and standardization news. The publication is a bi-monthly ...
Breaking Medicine News(10 mins):